3056013-66-9
Chemical Structure
Ganglioside GM3-d7
- CAS No.: 3056013-66-9
- Formula:C59H101D7N2O21
- Molecular Weight:1188.53
InChIKey: UIKPUUZBQYTDRX-YHCSRWKWSA-N
SMILES: OC([C@@]1(O[C@@]([C@H](NC(C)=O)[C@@H](O)C1)([H])[C@H](O)[C@H](O)CO)O[C@@H]2[C@H]([C@@H](O[C@H](CO)[C@@H]2O)O[C@]3([H])[C@H](O[C@@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(CCCCCCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)[C@H](O)[C@H]3O)CO)O)=O
Biological Activity: Ganglioside GM3-d7 is deuterium labeled Ganglioside GM3. Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia[1][1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ganglioside GM3-d7 | Ganglioside GM3-d7 is deuterium labeled Ganglioside GM3. Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ganglioside GM3 | 96.63% | Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Nihei W, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglioside GM3 in membrane microdomains. J Lipid Res. 2018 Nov;59(11):2181-2187. [Content Brief]
- [3]. Inokuchi JI, et al. Pathophysiological Significance of GM3 Ganglioside Molecular Species With a Particular Attention to the Metabolic Syndrome Focusing on Toll-Like Receptor 4 Binding. Front Mol Biosci. 2022 May 30;9:918346. [Content Brief]
